Seeking Novel Therapeutics for Anxiety Management

A global health company is seeking **novel therapeutics for chronic and situational anxiety**. Specifically, our client is interested in novel treatments with rapid onset that can be administered either daily (with a target of 4-6 hours of efficacy) for **situational anxiety**, or as a long-acting treatment (preferably monthly treatment) for **chronic anxiety**.

Therapeutics should have minimal side effects such as gastrointestinal issues, sedation, ataxia, and lethargy. Safety and efficacy studies in rodents, dogs and cats are preferred.

Approaches of Interest:

- Novel therapeutic approaches to address chronic anxiety and situational anxiety, preferably with validation in canine models
- The delivery method must be non-invasive - ideally oral or topical for daily dosing, or injectable for long-acting approaches
- The team is interested in serotonergics, 5-HT1A partial agonists, GABAergics, HPA axis mechanisms, and other novel mechanisms
- All modalities are of interest, with a preference for small molecules, peptides, monoclonal antibodies, and biopharma assets

Out of Scope:

- Approaches using hallucinogens/psychedelics or natural products
- SSRIs and SRNIs are not of interest unless rapid onset can be achieved

Developmental Stages of Interest:

- Opportunities should have *in vivo* validation of safety and efficacy, with a preference for canine data
- Our client is open to opportunities with human validation if there is potential for it to be repurposed for other species, and/or similar molecules/therapeutics that are available for development

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

- Biotech assets
- Spinout companies
- Research projects
- Technologies

Submissions

Please submit relevant, non-confidential opportunities to **Karla Schramm** at **kschramm@usf.edu**

Deadline: **21st February 2025 - 4:59 pm GMT**

Have any questions?
Contact **Karla Schramm** at **kschramm@usf.edu**